Omeros Reports Strong Q1 2026 Results with $56.1M Net Income, Driven by YARTEMLEA Launch
OMER has more than doubled off its 52-week low of $2.95 on elevated volume (2.1× avg).
Summary
Omeros Corporation announced robust first-quarter 2026 financial results, achieving a net income of $56.1 million and $9.9 million in net sales from its newly launched drug, YARTEMLEA.
Key Events · Earnings and Guidance · OMER
-
Shift to Profitability
Reported Q1 2026 net income of $56.1 million ($0.78 per share), a significant improvement from a $33.5 million net loss in Q1 2025. Non-GAAP adjusted net loss was $17.1 million.
-
Successful YARTEMLEA Launch
Generated $9.9 million in net sales for YARTEMLEA in its first quarter of commercial availability, indicating strong early adoption.
-
Strengthened Balance Sheet
Repaid $17.1 million of 2026 convertible notes, reducing total debt, and maintained $135.3 million in cash and short-term investments.
-
Share Repurchase Program
Repurchased 0.4 million shares for $4.2 million during the quarter, demonstrating commitment to shareholder value.
Analysis · OMER · Life Sciences
Omeros Corporation reported a significant financial turnaround in Q1 2026, moving from a net loss to a net income of $56.1 million. This positive shift was largely supported by the successful commercial launch of YARTEMLEA, which generated $9.9 million in net sales in its first quarter on the market. The company also strengthened its balance sheet by repaying $17.1 million in debt and executing a $4.2 million share repurchase program, signaling confidence in its financial health and future prospects.
At the time of this filing, OMER was trading at $14.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.95 to $17.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.